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Abstract
Incidence of diabetes is increasing worldwide at an alarming rate. Therefore, a proper understanding of the mecha-
nisms and efficient treatment of the disease is becoming increasingly important. The article briefly describes con-
troversies in type 1 diabetes (T1DM) pathogenesis and diagnosis (genetic background, accelerator hypothesis, new 
autoantibodies, new information on LADA – latent autoimmune diabetes in adults, and the role of TRAIL – tumor 
necrosis factor-related apoptosis-inducing ligand) and treatment (how to deal with fluctuations of blood glucose 
concentrations and the occurrence of hypoglycemia, the role of healthy lifestyle, especially physical exercise, and 
a proper diet, treatment of insulin resistance and the challenges in detecting diabetic neuropathy). Moreover, issues 
in the pathogenesis of macrovascular complications in type 2 diabetes (T2DM) are considered (novel risk factors 
– vascular hyperglycemic memory, hypoglycemia, altered profile of microRNAs expression, impaired function of 
vascular progenitor cells, altered fibrin clot properties and iron-induced blood coagulation). Modern treatment of 
T2DM, based on lifestyle intervention and antidiabetic drugs, is full of controversies and it seems that over time 
the number of uncertainties is constantly increasing. Recent trials have reported disappointing results in lifestyle 
intervention (LOOK-AHEAD) and antihyperglycemic treatment (ACCORD, SAVOR-TIMI 53, EXAMINE, con-
cerns about sulfonylureas safety). Moreover, there are considerable deviations from treatment targets that are rec-
ommended by the guidelines (blood glucose, hypertension, blood lipids) in real-life clinical practice in patients at 
different stages of the disease development. It seems that beneficial modification of the natural history of diabetes 
is unlikely in the foreseeable future unless we are able to obtain a more in-depth understanding of the pathomecha-
nisms of the disease (Adv Clin Exp Med 2013, 22, 6, 777–784).
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Streszczenie
Częstość występowania cukrzycy na świecie zwiększa się bardzo szybko. Dlatego coraz ważniejsze staje się odpo-
wiednie zrozumienie mechanizmów i skuteczne leczenie tej choroby. W artykule w skrócie opisano kontrowersje 
w poglądach na patogenezę i diagnostykę cukrzycy typu 1 (podłoże genetyczne, hipoteza akceleratora, nowe prze-
ciwciała, nowa wiedza o LADA – utajonej autoimmunologicznej cukrzycy u dorosłych i rola TRAIL – związanego 
z czynnikiem martwicy nowotworu ligandu wywołującego apoptozę) oraz leczenie (postępowanie z wahaniami 
stężenia glukozy we krwi, zapobieganie występowaniu hipoglikemii, rola zdrowego stylu życia, zwłaszcza aktyw-
ności fizycznej i odpowiedniej diety, leczenie insulinooporności, wykrywanie neuropatii cukrzycowej). Omówiono 
ponadto zagadnienia patogenezy powikłań makronaczyniowych cukrzycy typu 2 (nowe czynniki ryzyka – metabo-
liczna pamięć naczyniowa, hipoglikemia, zmiany profilu ekspresji mikroRNA, zaburzenia czynności naczyniowych 
komórek progenitorowych, zmiany właściwości skrzepu fibrynowego, zaburzenia krzepnięcia krwi wywołanego 
żelazem). Nowoczesne leczenie cukrzycy typu 2 z uwzględnieniem zmian stylu życia i stosowaniem leków prze-
ciwcukrzycowych jest nadal przedmiotem kontrowersji i wydaje się, że liczba wątpliwości nadal wzrasta. Ostatnie 
badania dotyczące modyfikacji stylu życia (LOOK-AHEAD) i leków przeciwcukrzycowych (ACCORD, SAVOR-
TIMI 53, EXAMINE, zastrzeżenia co do bezpieczeństwa pochodnych sulfonylomocznika) nie przyniosły oczeki-
wanych wyników dotyczących poprawy rokowania sercowo-naczyniowego. Co więcej, w codziennej praktyce kli-
nicznej występują istotne różnice między osiąganymi celami terapeutycznymi a zaleceniami do praktyki klinicznej 
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Controversies in the 
Pathogenesis and Diagnosis 
of Type 1 Diabetes in Adults 
Type 1 diabetes (T1DM) independent of age is 
an autoimmune disease with genetic background. 
HLA genes represent almost 50% of the familial 
risk of T1DM. Certain alleles of the HLA region, 
such as the HLA class II DR and DQ alleles, are 
mainly present in specific association with each 
other, a phenomenon known as linkage disequi-
librium. The genotype that confers the highest risk 
of T1DM is the heterozygosity of the two high-
risk HLA class II haplotypes: DR3 – DQ2 (DRB1* 
03 – – DQA1* 0501 – B1* 0201) and DR4 – DQ8 
(DRB1* 04 – DQA1* 0301 – B1* 0302). One or 
both of these haplotypes were found in more than 
95% of people with T1DM younger than 30 years 
but also in approximately 40–50% of the general 
population. Using a candidate gene approach, sev-
eral other non-HLA genes were found to be as-
sociated with increased risk of T1DM. These in-
clude genes encoding: insulin (INS), lymphocytic 
protein tyrosine phosphatase (PTPN22), the alpha 
chain of the IL-2 receptor (IL2R) and others main-
ly related to a specific and non-specific inflamma-
tory response [1]. Recently, the relationship be-
tween IL-6 gene-174 G/C polymorphism and risk 
of T1DM has been intensively studied, but the re-
sults have been inconsistent. A meta-analysis of 
more than 18.000 subjects has suggested a lack of 
association between IL-6 gene-174 G/C polymor-
phism and the risk of T1DM [2]. 
The pathomechanism of T1DM includes 2 dis-
tinct stages in genetically susceptible individuals. 
The 1st is triggering of an autoimmune reaction re-
sulting in autoantibodies against specific islet cells 
auto-antigens associated with gradual beta cell kill-
ing. The 2nd is loss of beta-cell secretory function 
manifested in infancy by the loss of 1st phase of in-
sulin release and finally absolute deficiency of in-
sulin. According to the accelerator hypothesis, the 
increased rate of beta-cell apoptosis and insulin re-
sistance modulate the timing of clinical onset and 
subsequent course of autoimmune diabetes. How-
ever, the autoimmune process is thought to be the 
main accelerator of beta-cell destruction both be-
fore and after onset of T1DM [3]. 
Diagnosis of T1DM becomes increasingly dif-
ficult to distinguish from other types of diabetes 
after about 30–35 years of age. The term LADA 
(latent autoimmune diabetes in adults) was intro-
duced to describe this subgroup of adult pheno-
typic type 2 diabetes but positive for an autoanti-
body to glutamine acid decarboxylase (GAD) [4]. 
LADA is a slowly progressive form of autoimmune 
disease causing diabetes and is characterized by 
the presence of serum autoantibodies to pancre-
atic antigens. 
We have previously shown that a patient’s 
age at autoimmune diabetes onset does not deter-
mine the clinical and biochemical presentation at 
diagno sis. The severity of the autoimmune process 
is reflected by the number of anti-islet cell antibod-
ies. Patients with multiple autoantibodies seem to 
be at higher risk of having more pronounced de-
struction of β-cells and insulin deficiency. The 
IA-2A positivity was equally frequent in younger 
and older patients, and for the group of patients 
it was the only anti-islet antibody detected. These 
results of our previous study definitely highlight 
the potential importance of IA-2A in screening for 
autoimmunity in newly diagnosed adult diabetic 
patients [4].
Recently, a new autoantibody has been re-
vealed to be connected with autoimmune diabe-
tes. Zinc transporter 8 (ZnT8) autoantibodies are 
believed to be part of the autoimmune process. 
The gene that is responsible for coding ZnT8 is 
named SCL30A8 and is localized on chromosome 
8q24.11 [5]. ZnT8A are present in both juvenile-
onset T1DM and in adult onset autoimmune di-
abetes. It was noticed that the number of autoan-
tibody-negative patients was lower when a ZnT8 
assay aside from other measurements was per-
formed. Lampasona et al. revealed that the pres-
ence of ZnT8A was connected with younger age 
and high GADA titer among adult-onset autoim-
mune diabetes [6].
TRAIL (tumor necrosis factor-related apopto-
sis-inducing ligand) is a transmembrane protein 
expressed on most cells that regulates homeosta-
sis of the immune system and inflammatory re-
action [7]. There is emerging evidence to support 
an association between TRAIL and diabetes. The 
main mechanism of beta-cell destruction is apop-
tosis. T cell induced death seems to be the main 
(stężenie glukozy we krwi, ciśnienie tętnicze, stężenie lipidów we krwi) we wszystkich stadiach rozwoju choroby. 
Wydaje się, że osiągnięcie korzystnej modyfikacji przebiegu klinicznego u chorych na cukrzycę jest mało prawdo-
podobne, jeżeli nie uda się bardziej szczegółowo poznać patomechanizmów choroby i jej powikłań (Adv Clin Exp 
Med 2013, 22, 6, 777–784).
Słowa kluczowe: cukrzyca typu 1, cukrzyca typu 2, cukrzyca o podłożu autoimmunologicznym, powikłania serco-
wo-naczyniowe cukrzycy.
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source of TRAIL in the pancreas in T1DM. An as-
sociation between TRAIL and autoimmune diabe-
tes has been noticed, but their role is controversial 
because both apoptotic and protective roles have 
been described [8]. It is not surprising that a re-
lationship between TRAIL and insulin resistance, 
obesity and cancer has been noted. TRAIL reflects 
the inflammatory process that plays a key role in 
the listed pathology. 
Controversies in the 
Management of Type 1 
Diabetes
The therapeutic goals in patients with T1DM 
include prevention of the chronic and acute com-
plications of diabetes while maintaining good 
quality of life. Established risk factors for micro-
vascular complications in T1DMi include chron-
ic hyperglycemia, hypertension and dyslipidemia. 
Maintaining good metabolic control is effective in 
decreasing the risk of chronic complications, but 
new approaches are needed to control the resid-
ual risk. 
Measurement of glycation products, such as 
glycated hemoglobin, fructosamine and glycated 
albumin, reflect the average blood glucose concen-
tration from a time interval preceding the assay, 
but do not account for the fluctuations of blood 
glucose concentrations and the occurrence of hy-
poglycemia [9]. This also applies to the novel tech-
niques of noninvasive measurement of skin au-
tofluorescence to detect advanced glycation end 
products (AGEs) accumulation in the skin that 
seems to reflect glycemic control over periods of 
time much longer than HbA1c assay [10]. Evi-
dence from preclinical studies shows that fluctu-
ating glucose levels may increase oxidative stress 
and have an even more deleterious effect than con-
stantly high glucose exposure [11]. One may there-
fore hypothesize that control of daily blood glu-
cose fluctuations, in addition to management of 
chronic hyperglycemia (as measured by HbA1c) in 
diabetic patients, may protect against micro- and 
macrovascular disease. 
The relationship between glycemic variabili-
ty and the development of chronic complications 
is controversial and long-term observations and 
standardized methods of measurement of glyce-
mic variability are needed to clarify this issue [12]. 
High glycemic variability is also associated with 
severe hypoglycemia in patients with T1DM [13]. 
Despite the lack of definitive evidence on the in-
fluence of glycemic variability on hard endpoints 
other than hypoglycemia, contemporary and 
emerging treatment options help reduce fluctua-
tions of glycemic. As a consequence, increased in-
cidence of hypoglycemia is not an inevitable con-
sequence of the intensification of glycemic control. 
In patients on intensive insulin therapy using mul-
tiple insulin injections, switching to long acting in-
sulin analogue may help reduce the events of hy-
poglycemia, particularly during the night [14]. 
New methods of controlling glycemic variability 
range from the use of continuous glucose moni-
toring systems (CGMS), with or without the possi-
bility to discontinue insulin delivery in case of hy-
poglycemia, to the increasingly tested systems with 
automatic adjustment of insulin delivery depend-
ing on glycemic (closed loop insulin delivery) [15]. 
Attempts are also being made to use both insulin 
and glucagon (dual hormone therapy) to better 
approximate the physiologic mechanism of glyce-
mic control [16]. According to a recent meta-anal-
ysis [17], the use of CGMS in patients with T1DM 
treated with intensive insulin therapy (multiple 
daily insulin injections or continuous subcutane-
ous insulin infusion) was associated with a small 
(0.3%) yet significant reduction in HbA1c, with si-
multaneously reduced exposure to hypoglycemia. 
It should be underlined, however, that according 
to the clinical guidelines and common practice, the 
use of CGM requires close involvement of the pa-
tient in the treatment process and the efficacy of 
CGM largely depends on patient selection, educa-
tion and close follow-up [18].
In T1DM, the presence and degree of residu-
al insulin secretion is associated with better meta-
bolic control reflected by a decrease in the episodes 
of hyperglycemia, diabetic ketoacidosis (DKA) and 
also hypoglycemia. Clinical remission of T1DM is 
a phase of the disease when insulin secretion is 
present to a significant degree, sometimes compa-
rable to non-diabetic individuals. It is unknown if 
the presence or duration of partial remission may 
be associated with sustained long-term residu-
al insulin secretion and a decrease in the risk of 
chronic complications. However, the partial re-
mission phase serves as a model to test how life-
style or pharmacological interventions are effective 
in maintaining insulin secretion in patients with 
type 1 diabetes. For instance, it was shown that cig-
arette smoking is associated with a shortening of 
partial remission [19]. 
Evidence is accumulating that physical activ-
ity in many ways positively influences the course 
of T1DM. Sedentary lifestyle has been associated 
with poor glycemic control in young patients with 
T1DM [20]. Some studies have demonstrated an 
improvement in glycated hemoglobin (HbA1c) af-
ter physical activity [21]. The influence of physical 
activity on glycemic control may also depend on 
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the form of training. The results of a recent meta-
analysis demonstrate that only regular aerobic ex-
ercise programs significantly improved acute and 
chronic glycemic control [22]. Moreover, the com-
position of training sessions may also have a role in 
maintaining metabolic control, as the addition of 
brief bouts of high-intensity exercise to aerobic ex-
ercise was found to decrease the risk of late hypo-
glycemic episodes occurring after training [22]. Of 
note, in the studies that demonstrated the positive 
effect of exercise on glycemic control, the decrease 
in HbA1c was not associated with a significant in-
crease in the frequency of hypoglycemia. An in-
crease in physical activity is commonly associated 
with decreased insulin requirement, which may be 
explained mainly by an increased insulin-indepen-
dent glucose uptake by myocytes and increased pe-
ripheral insulin sensitivity [23]. Available evidence 
suggests the positive influence of physical activity 
on beta-cell function in patients with T2DM, over-
weight non-diabetic subjects, and NOD mice and 
a pilot trial has been designed recently to test this 
effect in adults with newly diagnosed T1DM [24].
The effect of physical activity on the hard end-
points in the course of T1DM appears to be bene-
ficial, although the evidence on this is based main-
ly on retrospective studies, such as the FinnDiane 
study [25]. Large prospective studies are needed to 
confirm this effect in patients with type 1 diabe-
tes. Not only leisure-time physical activity, but also 
professional practice of competitive sports appears 
to be safe and beneficial for educated patients with 
well-controlled type 1 diabetes. 
Insulin resistance is common in T1DM and 
is associated with an increased risk of its chronic 
complications [26]. In patients with T1DM, phys-
ical activity may decrease oxidative stress and re-
verse endothelial dysfunction [26], both of these 
effects may result in increased insulin sensitivity. 
Among other lifestyle components, short sleep du-
ration was found to be associated with insulin re-
sistance in patients with T1DM [27]. Also, ciga-
rette smoking, triggering hormonal responses that 
are counter-regulatory to insulin, decreases insu-
lin sensitivity [28]. 
Some trials addressed the efficacy of metformin, 
the drug registered in type 2 diabetes that mainly 
decreases hepatic insulin resistance, as an add-on 
treatment in T1DM. In a recent meta-analysis, met-
formin use was associated with a statistically and 
clinically significant reduction in HbA1c (0.6–0.9%), 
along with reduced insulin requirement, decreased 
body weight and serum total cholesterol concentra-
tion. Moreover, the metformin treatment appeared 
to be safe, with an increased prevalence of hypogly-
cemia as the main adverse event [29].
In the current approach, the diet recommended 
to the majority of patients with T1DM does not 
differ from a healthy diet suggested for the non-
diabetic population. Restrictions on the consistent 
day-to-day carbohydrate content of meals is an 
important consideration where premixed insulin 
or fixed basal-bolus treatment are used. Patients 
who are well educated and adjust insulin doses 
to the carbohydrate content of the meals do not 
need such restrictions to achieve adequate control 
of glycemic. The use of the glycemic index (GI) in 
food choices may be beneficial in maintaining nor-
moglycemia and is increasingly popular in T1DM 
patients, but they must be advised not to increase 
saturated fat intake when introducing the low-GI 
diet. Apart from its pro-atherogenic effect, in the 
DCCT cohort, increased fat intake was associated 
with worse glycemic control independent of exer-
cise and BMI [30]. Despite the fact that products 
with a high glycemic index are not strictly forbid-
den for patients with T1DM, especially those us-
ing flexible intensive insulin treatment, a rapid rise 
of postprandial glycemia following these meals is 
difficult to control even with rapid-acting insu-
lin analogues. The other cause of increased fat in-
take in some patients with T1DM may be low-car-
bohydrate nutrition used in an effort to minimize 
the need for insulin injections or to lose weight. As 
a consequence, many people with T1DM consume 
a diet higher in fat and saturated fat than members 
of the general population [31]. The frequent in-
take of high-GI snacks by children and adolescents 
has led to obesity, dyslipidemia and poor glyce-
mic control [32]. Interestingly, frequent consump-
tion of diet beverages is also associated with poor 
metabolic control of T1DM, similarly to the con-
sumption of sweetened beverages, possibly being 
a marker of an unhealthy diet pattern [32]. Many 
young people with T1DM present a lifestyle associ-
ated with low attention to dietary choices and fre-
quent consumption of fast-food. Apart from other 
negative effects, this diet is usually associated with 
a very high intake of food rich in trans unsaturat-
ed fatty acids (from hydrogenated vegetable oils) 
and food additives. 
Among the diagnostic strategies of detecting the 
chronic complications of type 1 diabetes, the most 
challenging one is early detection of diabetic neu-
ropathy, since the sensitivity of the widely-used tests 
is low when compared with the methods of screen-
ing for diabetic retinopathy or diabetic kidney dis-
ease. The diagnostic procedures currently used for 
research purposes, including the measurement of 
intraepidermal nerve fiber density [33] and mea-
surement of nerve conduction velocity [34], are in-
vasive and complex, which limits their widespread 
use. Examining the degree of retinal degeneration 
using optical coherence tomography (OCT) enables 
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measurement of retinal thickness with identification 
of individual retinal layers, revealing manifestations 
of both neuropathy and retinopathy [35]. Novel 
noninvasive tools for diabetic neuropathy screening 
may check sudomotor dysfunction, which indirect-
ly reveals small fiber dysfunction, with high sensi-
tivity and modest specificity [36].
Controversies in 
the Pathogenesis of 
Macrovascular Complications 
in Type 2 Diabetes
Besides ageing of the population, lifestyle 
changes and lower physical activity leading to 
a higher prevalence of obesity are responsible for the 
fact that the incidence of type 2 diabetes (T2DM) is 
increasing worldwide at an alarming rate [37]. In 
a recent study, it was demonstrated that 16.3% of 
the Polish population is affected by various carbo-
hydrate metabolism disorders (6.8% of people had 
diabetes and 9.5% impaired fasting glucose) [38]. 
The vascular complications of T2DM caused by 
atherosclerosis are the most serious manifestations 
of the disease and are largely responsible for de-
creased life expectancy in those patients [39]. Al-
though epidemiological evidence clearly suggests 
that diabetic hyperglycemia is a major risk factor 
for macrovascular complications, recent clinical 
trials have clearly demonstrated that intensive glu-
cose lowering treatment shows limited benefits on 
the cardiovascular (CV) system and all cause mor-
tality in patients with T2DM and CV disease [39]. 
Therefore, to improve the therapeutic approach, it 
is necessary to go from bedside-to-bench again to 
better understand the pathomechanisms of macro-
vascular complications in T2DM. 
While the vascular complications of diabe-
tes are mainly due to insulin resistance and hy-
perglycemia leading to oxidative stress and clus-
tering with arterial hypertension, dyslipidemia 
as well as genetic susceptibility, novel risk fac-
tors have recently come under investigation [37]. 
They include, among others, vascular hyperglyce-
mic memory, the pathophysiological consequenc-
es of hypoglycemia, an altered profile of microR-
NAs expression and impaired function of vascular 
progenitor cells [39]. Moreover, individuals with 
T2DM are also at increased risk of thrombotic cor-
onary events, which are driven by an increase in 
platelet activation, enhanced thrombin generation 
and altered fibrin clot properties [40]. 
Recently, a novel pathway of blood coagu-
lation was described which might have impor-
tant implications for T2DM patients [41]. It was 
demonstrated that fibrinogen, besides being a pre-
cursor to fibrin, can be converted into an insolu-
ble polymer by hydroxyl radicals which are gener-
ated with the involvement of trivalent ferric ions, 
without the participation of any redox agent [41]. 
Therefore, the role of iron overload might be 
a novel pathomechanism for the pro-thrombotic 
state and cardiovascular complications observed in 
diabetes and a new target for therapy. 
Coagulation in diabetic patients can also be af-
fected by even mild hypoglycemia. Very recently, 
it was shown that even a single episode of hypo-
glycemia induces pro-thrombotic changes in the 
fibrin network and aggravates subclinical inflam-
mation, and these effects are sustained for at least 
1 week [42].
It is becoming clear that future treatment par-
adigms for T2DM patients will need to encompass 
a broader spectrum of pathophysiological determi-
nants than previously expected.
Controversies  
in the Management  
of Type 2 Diabetes
Modern treatment of T2DM, based on lifestyle 
intervention and antidiabetic drugs, is full of con-
troversies and it seems that over time the num-
ber of uncertainties constantly increases. Similarly 
to T1DM, recommendations for lifestyle modifi-
cation through healthy diet and increased physi-
cal activity have been the foundation on which all 
additional T2DM therapies should rest. Unfortu-
nately, recently a large, prospective and random-
ized LOOK-AHEAD Trial on lifestyle interven-
tion in obese T2DM patients was stopped early 
after a median follow-up of almost 10 years, when 
interim analyses suggested neutral effects on car-
diovascular outcomes, a finding that was consis-
tent across all reported subgroups [43].
In 2013, there is an ever-increasing range of 
antihyperglycemic options for the treatment of pa-
tients with T2DM [44]. Although all of the guide-
lines and regulatory agencies consider lowering 
blood glucose and glycated hemoglobin in T2DM 
an approvable end point, very intensive glycemic 
control might be associated with increased mor-
tality in those patients [44, 45]. There are also re-
curring controversies regarding higher cancer risk 
in patients treated with some hypoglycemic med-
ications, although the majority of the available 
studies assessing that effect have significant lim-
itations [46]. On the other hand, better glycemic 
control delays the onset and progression of micro-
vascular complications [39]. Therefore the choice 
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of optimal drugs and treatment algorithms be-
comes a major controversy [44]. Unfortunately, 
direct and fair comparisons between drugs and 
regimens are lacking and the clinician is left to de-
cide among agents with different safety and bur-
den profiles [44]. One such controversy concerns 
sulfonylurea, which is, in some countries (includ-
ing Poland), a major and widely accessible antidi-
abetic drug. In a very recent retrospective study 
of 92.498 patients with T2DM, first-line therapy 
with sulfonylurea increased the risk for all-cause 
mortality by 58% when compared with metfor-
min [47]. Recently, sulfonylurea was also respon-
sible for a significant increase in hypoglycemia 
rates in major clinical studies involving dipepti-
dyl peptidase 4 (DPP-4) inhibitors and this might 
be partly responsible for the neutral effect of that 
newer generation of antidiabetic drugs on CV 
outcomes [45].
Therefore, it seems that glycemic control is not 
the only or the most important goal for most pa-
tients with T2DM and special care should be tak-
en to treat patients’ concomitant risk factors for 
macrovascular complications, especially hyperten-
sion and hyperlipidemia. Unfortunately, consid-
erable deviations from the treatment targets that 
are recommended by the guidelines exist in real-
life clinical practice among patients at different 
stages of the disease development. In newly diag-
nosed T2DM patients in an ARETAEUS study, on-
ly 1.4% of the patients met all their treatment goals 
(HbA1c, blood pressure, and lipid levels), and as 
much as 51% did not meet any of the targets [48]. 
In a recent OPTIMO study performed in specialty 
outpatient clinics in Poland, it was demonstrated 
that the majority of referred patients do not meet 
the treatment goals recommended by the guide-
lines (67% for hyperlipidemia and 49% for hy-
pertension) [49]. This might be due to underuse 
of cardiovascular drugs in T2DM patients, despite 
their proven efficacy. In the Kardia-Pol registry in 
primary care, only 70% of T2DM patients received 
angiotensin-blocking agents and 64% were treat-
ed with statins, despite the high prevalence of the 
above-mentioned risk factors [50]. Assuming that 
adherence to the current clinical practice guide-
lines is beneficial for patients, it is crucial that both 
practitioners and patients have increased aware-
ness of these guidelines and of the ways to achieve 
and maintain treatment goals [48].
Conclusions
The most effective prevention of diabetic com-
plications would likely be to safely achieve perfect 
metabolic control and to successfully treat other 
risk factors for micro- and macrovascular compli-
cations. It seems that achievement of this goal is 
unlikely in the foreseeable future.
As a wealth of mechanistic information is accu-
mulating regarding the pathophysiology of diabetes 
and its complications, it is becoming clear that with-
out proper understanding of those complex mech-
anisms, the discovery of beneficial treatment regi-
mens for diabetic patients will not be possible.
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